TR200102959T2 - İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri - Google Patents

İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri

Info

Publication number
TR200102959T2
TR200102959T2 TR2001/02959T TR200102959T TR200102959T2 TR 200102959 T2 TR200102959 T2 TR 200102959T2 TR 2001/02959 T TR2001/02959 T TR 2001/02959T TR 200102959 T TR200102959 T TR 200102959T TR 200102959 T2 TR200102959 T2 TR 200102959T2
Authority
TR
Turkey
Prior art keywords
bicyclic heteroaryl
compounds substituted
heteroaryl compounds
integrin antagonists
compounds
Prior art date
Application number
TR2001/02959T
Other languages
English (en)
Inventor
David Clark Edward
Robert Eastwood Paul
Victor Harris Neil
Mccarthy Clive
David Morley Andrew
Dennis Pickett Stephen
Original Assignee
Aventis Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9908355.2A external-priority patent/GB9908355D0/en
Application filed by Aventis Pharma Limited filed Critical Aventis Pharma Limited
Publication of TR200102959T2 publication Critical patent/TR200102959T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Bulus R1Z1-Het-L1-Ar1-L2-Y genel formül (I)'e ait fizyolojik açidan aktif bilesiklerle; ve ilgili N-oksitlerle, ve bunlarin ön ilaçlariyla; ve bu gibi bilesiklerin ve bunlarin N-oksitlerinin ve ön ilaçlarinin farmasötik açidan kabul gören tuzlari ve solvatlariyla (örn., hidratlar) ilgilidir. Bu bilesikler, degerli farmasötik özelliklere,özellikle de VCAM-1 ve fibronektinin integrin VLA-4 (alfa4 beta1) ile etkilesimini düzenleyebilme kabiliyetine sahiptir.
TR2001/02959T 1999-04-12 2000-04-12 İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri TR200102959T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9908355.2A GB9908355D0 (en) 1999-04-12 1999-04-12 Chemical compounds
US14147099P 1999-06-29 1999-06-29

Publications (1)

Publication Number Publication Date
TR200102959T2 true TR200102959T2 (tr) 2002-04-22

Family

ID=26315408

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02959T TR200102959T2 (tr) 1999-04-12 2000-04-12 İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri

Country Status (24)

Country Link
US (1) US6706738B2 (tr)
EP (1) EP1183254B1 (tr)
KR (1) KR20010110750A (tr)
CN (1) CN1350534A (tr)
AT (1) ATE286896T1 (tr)
AU (1) AU769554B2 (tr)
BG (1) BG106083A (tr)
BR (1) BR0010599A (tr)
CA (1) CA2369728A1 (tr)
CZ (1) CZ20013661A3 (tr)
DE (1) DE60017389T2 (tr)
EE (1) EE200100528A (tr)
ES (1) ES2231179T3 (tr)
HK (1) HK1044937A1 (tr)
HR (1) HRP20010732A2 (tr)
HU (1) HUP0200803A3 (tr)
IL (2) IL145748A0 (tr)
MX (1) MXPA01010231A (tr)
NO (1) NO20014951L (tr)
NZ (1) NZ514602A (tr)
PL (1) PL351433A1 (tr)
SK (1) SK14372001A3 (tr)
TR (1) TR200102959T2 (tr)
WO (1) WO2000061580A1 (tr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1346982B1 (en) 2000-12-28 2011-09-14 Daiichi Pharmaceutical Co., Ltd. Vla-4 inhibitors
CA2480638C (en) * 2002-03-29 2013-02-12 Chiron Corporation Substituted benzazoles and use thereof as raf kinase inhibitors
CA2770493A1 (en) 2003-07-24 2005-02-03 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
CN1933839A (zh) 2004-01-23 2007-03-21 安进公司 化合物和使用方法
JP2007518823A (ja) 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
CA2576170A1 (en) * 2004-08-16 2006-03-02 The Procter & Gamble Company 2-(amino or substituted amino)-5, 6-substituted phenol compounds, dyeing compositions containing them, and use thereof
DE102004041137A1 (de) * 2004-08-25 2006-03-02 Wella Ag o-Aminophenol-Derivate und diese Verbindungen enthaltende Färbemittel
US7235688B1 (en) 2004-11-04 2007-06-26 University Of Notre Dame Du Lac Process for preparing histone deacetylase inhibitors and intermediates thereof
US20070021612A1 (en) * 2004-11-04 2007-01-25 University Of Notre Dame Du Lac Processes and compounds for preparing histone deacetylase inhibitors and intermediates thereof
CA2587642C (en) 2004-11-30 2013-04-09 Amgen Inc. Substituted heterocycles and methods of use
US7514460B2 (en) 2004-12-22 2009-04-07 4Sc Ag Benzazole analogues and uses thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
US7553854B2 (en) 2006-04-19 2009-06-30 Novartis Vaccines And Diagnostics, Inc. 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
US7931838B2 (en) * 2006-08-31 2011-04-26 Virginia Tech Intellectual Properties, Inc. Method for making oriented single-walled carbon nanotube/polymer nano-composite membranes
US7795254B2 (en) * 2007-10-29 2010-09-14 Amgen Inc. Benzomorpholine derivatives and methods of use
UY32138A (es) * 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
UY32470A (es) 2009-03-05 2010-10-29 Boehringer Ingelheim Int Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
US8759537B2 (en) 2010-08-20 2014-06-24 Boehringer Ingelheim International Gmbh 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents
US8486968B2 (en) 2010-12-10 2013-07-16 Boehringer Ingelheim International Gmbh Compounds
US8466186B2 (en) 2010-12-10 2013-06-18 Boehringer Ingelheim International Gmbh Compounds
UY33779A (es) 2010-12-10 2012-07-31 Boehringer Ingelheim Int ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
WO2014145561A2 (en) 2013-03-15 2014-09-18 Protagonist Therapeutics, Inc. Hepcidin analogues and uses therof
ES2890600T3 (es) * 2014-05-16 2022-01-20 Protagonist Therapeutics Inc Péptidos de tioéter antagonistas de integrina alfa4beta7
KR102482790B1 (ko) 2014-07-17 2022-12-29 프로타고니스트 테라퓨틱스, 인코포레이티드 인터루킨-23 수용체의 경구용 펩티드 억제제 및 염증성 장 질환을 치료하기 위한 그의 용도
US9809623B2 (en) 2014-10-01 2017-11-07 Protagonist Therapeutics, Inc. α4β7 peptide monomer and dimer antagonists
WO2016054445A1 (en) 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. Novel cyclic monomer and dimer peptides having integrin antagonist activity
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2017117411A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
CN109195618A (zh) 2016-03-23 2019-01-11 领导医疗有限公司 用于合成α4β7肽拮抗剂的方法
EP3681900A4 (en) 2017-09-11 2021-09-08 Protagonist Therapeutics, Inc. OPIOID AGONIST PEPTIDES AND THEIR USES
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
CN114341161A (zh) 2019-07-10 2022-04-12 领导医疗有限公司 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途
WO2021146454A1 (en) 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JOP20220169A1 (ar) 2020-01-15 2023-01-30 Janssen Biotech Inc مثبطات ببتيدية لمستقبلة انترلوكين-23 واستخدامها في معالجة الأمراض الالتهابية
EP4146639A1 (en) 2020-05-06 2023-03-15 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
KR20230110570A (ko) 2020-11-20 2023-07-24 얀센 파마슈티카 엔.브이. 인터류킨-23 수용체의 펩티드 억제제의 조성물
EP4267574A1 (en) 2020-12-23 2023-11-01 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202334139A (zh) 2021-11-09 2023-09-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳氧基苯并咪唑及氮雜苯并咪唑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9801716A (es) * 1995-08-30 1998-05-31 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido aminobenzoico azaciclico, como antagonistas de integrina.
NZ507292A (en) * 1998-04-10 2003-12-19 G Heterocyclic glycyl beta-alanine derivatives useful as vitronectin antagonists
DK1153017T3 (da) * 1999-02-16 2006-07-17 Aventis Pharma Ltd Bicykliske forbindelser og deres anvendelse som integrinreceptorligander

Also Published As

Publication number Publication date
DE60017389D1 (de) 2005-02-17
WO2000061580A1 (en) 2000-10-19
IL145748A (en) 2007-02-11
NO20014951D0 (no) 2001-10-11
DE60017389T2 (de) 2006-03-02
ATE286896T1 (de) 2005-01-15
CA2369728A1 (en) 2000-10-19
US6706738B2 (en) 2004-03-16
CZ20013661A3 (cs) 2002-01-16
US20020173506A1 (en) 2002-11-21
CN1350534A (zh) 2002-05-22
EP1183254B1 (en) 2005-01-12
MXPA01010231A (es) 2003-07-21
NZ514602A (en) 2003-06-30
EP1183254A1 (en) 2002-03-06
HK1044937A1 (zh) 2002-11-08
HRP20010732A2 (en) 2002-12-31
ES2231179T3 (es) 2005-05-16
AU3981600A (en) 2000-11-14
HUP0200803A3 (en) 2002-12-28
BR0010599A (pt) 2002-02-13
SK14372001A3 (sk) 2002-06-04
IL145748A0 (en) 2002-07-25
KR20010110750A (ko) 2001-12-13
AU769554B2 (en) 2004-01-29
HUP0200803A2 (hu) 2002-07-29
BG106083A (en) 2002-05-31
EE200100528A (et) 2003-02-17
NO20014951L (no) 2001-12-11
PL351433A1 (en) 2003-04-22

Similar Documents

Publication Publication Date Title
TR200102959T2 (tr) İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri
TR200100588T2 (tr) Hücre yapışmasının önlenmesini modüle eden aza-bisikleler.
CA2303848A1 (en) Substituted anilides
TR200102489T2 (tr) 3-Fenilpiridin Türevleri ve bunların NK-1 alıcı antagonistler olarak kullanılması
MY124390A (en) Substituted bicyclic derivatives useful as anticancer agents
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
BG66085B1 (bg) Фенилаланинови производни
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
PL315035A1 (en) Cyclic amide derivatives as antagonistic substances in respect to neurokinin a
ES2139760T3 (es) Nuevas lactamas sustituidas con 4-piperidinilo con propiedades antagonistas del receptor de neurokinina 2 en el tratamiento del asma.
MXPA04000278A (es) Uso de antagonistas del receptor nk-1 con estructura piridinica para tratamiento de lesiones cerebrales, espinales o neuronales.
MXPA03008215A (es) Inhibidores de integrina alfa v beta 6.
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
EA200200119A1 (ru) β-КАРБОЛИНОВЫЕ ЛЕКАРСТВЕННЫЕ ПРОДУКТЫ
DE60027700D1 (de) Bicyclische verbindungen und ihre verwendung als integrinrezeptorliganden
BR9909486A (pt) Compostos calcilìticos
DK0733051T3 (da) Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister
WO2002036553A3 (en) Substituted alkanoic acids
DE69829215D1 (de) Substituierte beta-alaninen
WO2001064659A3 (en) Indane derivatives and their use as cell adhesion inhibitors
WO2001029066A3 (en) Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them
MXPA02012015A (es) Ligandos de receptores para integrinas.
EA200300226A1 (ru) ГЕМ-ЗАМЕЩЕННЫЕ АНТАГОНИСТЫ ИНТЕГРИНА αvβ3
TR199900013T2 (tr) Yeni bilesikler.
TR200100354T2 (tr) NK-2 Antagonist hareketine sahip monosiklik bileşimler ve oluşumlar.